Physician profile
Robert A Greer
NPI 1912386194
$10,924.59
in general payments reported to CMS, 2019-2025
37 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 82% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $277 · 2021: $1,223 · 2022: $1,650 · 2023: $1,588 · 2024: $2,358 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,987 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,987.27 |
| Education | $277.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,848.33 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,535.75 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $1,312.93 | 2019-2025 | Haegarda, Andembry |
| Genzyme Corporation | $1,255.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,116.80 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $550.39 | 2020-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $418.24 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $332.30 | 2021-2024 | |
| Optinose US, INC. | $316.97 | 2020-2025 | |
| Incyte Corporation | $300.55 | 2024-2025 | Opzelura |
| Biocryst US Sales Co., LLC | $233.38 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $223.30 | 2022-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $204.94 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Kaleo, INC. | $196.71 | 2021-2024 | Auvi-Q |
| Amgen INC. | $139.18 | 2021-2024 | Tezspire |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.